Date:	March 29, 2023
Your Name:_	_Katherine S. Crow
<b>Manuscript T</b>	itle: Pivoting to Telemedicine in a Single-Day Multidisciplinary Liver Tumor Clinic During COVID-19: The Texas
Liver Tumor C	enter (TLTC) Experience
Manuscript n	umber (if known):APM-23-357

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	_X_None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past _X_None	36 months
3	Royalties or licenses	_X_None	
4	Consulting fees	_x_None	

5	Payment or honoraria for	_x_None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_x_None	
	testimony		
7	Support for attending meetings and/or travel	_X_None	
8	Patents planned, issued or	_X_None	
	pending		
_			
9	Participation on a Data	_X_None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	_X_None	
10	in other board, society,	_X_None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_X_None	
12	Receipt of equipment,	_X_None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	_X_None	
	financial interests		
Dloa	ise summarize the above co	nflict of interest in the fall	owing hove

None			

Please place an "X" next to the following statement to indicate your agreement:

Date: March 30, 2023	2.
Your Name: Fred Poordad	
Manuscript Title: Pivoting to Telemedicine in a Single-Day Multidisciplinary Liver Tumor Clinic I	Ouring
Manuscript number (if known):N/A	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All access of family and access	- V	planning of the work
1	All support for the present	_X_None	
	manuscript (e.g., funding,		
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
	No time innit for this item.		
_		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).	V	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
	•		
7	Support for attending meetings and/or travel	X_None	
		_	
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	<u>k</u> _None	
	financial interests		
Plea	se summarize the above co	nflict of interest in the follow	ing box:

Please place an "X" next to the following statement to indicate your agreement:

<u>χ</u> I certify that I have answered every question and have not altered the wording of any of the questions on this form.



Payment or honoraria for

None

Date: March 29, 2023 Your Name: Glenn Halff

Manuscript Title: Pivoting to Telemedicine in a Single-Day Multidisciplinary Liver Tumor Clinic During COVID-19: The Texas

Liver Tumor Center (TLTC) Experience

Manuscript nur	mber (i	f known)	:	APM-23-357			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	_X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X_None	
3	Royalties or licenses	X_None	
4	Consulting fees	_X_None	

5	Payment or honoraria for	_X_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	V Name	
6	Payment for expert testimony	_X_None	
	,		
7	Support for attending meetings and/or travel	_X_None	
	meetings unapor travel		
8	Patents planned, issued or	_X_None	
	pending		
9	Participation on a Data	_X_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_X_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
	Stock of Stock options	_X_None	
12	Receipt of equipment,	_X_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	X None	
13	financial interests		
	inialiciai interests		
Dlos	see summarize the above co	unflict of interest in the fol	lowing hov:

None			

Please place an "X" next to the following statement to indicate your agreement:

Date: March 29, 2023

Your Name: Francisco Cigarroa

Manuscript Title: Pivoting to Telemedicine in a Single-Day Multidisciplinary Liver Tumor Clinic During COVID-19: The Texas

<u>Liver Tumor Center (TLTC) Experience</u>

Manuscript number (if known): <u>APM-23-357</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	_X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X_None	
3	Royalties or licenses	_X_None	
4	Consulting fees	_X_None	

5	Payment or honoraria for	_X_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	V Name	
6	Payment for expert testimony	_X_None	
7	Support for attending meetings and/or travel	_X_None	
	meetings una/or traver		
8	Patents planned, issued or	_X_None	
	pending		
9	Participation on a Data	_X_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_X_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	_X_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	_X_None	
	financial interests		
	asa summariza tha abaya sa		

None			

Please place an "X" next to the following statement to indicate your agreement:

Date: March 29, 2023 Your Name: Eugenia Tsai

Manuscript Title: Pivoting to Telemedicine in a Single-Day Multidisciplinary Liver Tumor Clinic During COVID-19: The Texas

<u>Liver Tumor Center (TLTC) Experience</u>

Manuscript number (if known): <u>APM-23-357</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_X_None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
	The time limit for this term		
		Time frame: past	36 months
2	Grants or contracts from	_X_None	30 months
_	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	X_None	
		_	
4	Consulting fees	_X_None	

5	Payment or honoraria for	_X_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events	V Name	
6	Payment for expert testimony	_X_None	
7	Support for attending meetings and/or travel	_X_None	
	meetings una/or traver		
8	Patents planned, issued or	_X_None	
	pending		
9	Participation on a Data	_X_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_X_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	_X_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	_X_None	
	financial interests		
	asa summariza tha abaya sa		

None			

Please place an "X" next to the following statement to indicate your agreement:

Date: March 29, 2023
Your Name: Irma Infante

Manuscript Title: Pivoting to Telemedicine in a Single-Day Multidisciplinary Liver Tumor Clinic During COVID-19: The Texas

<u>Liver Tumor Center (TLTC) Experience</u>

Manuscript number (if known): \_\_APM-23-357

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_X_None	
	manuscript (e.g., funding,		
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_X_None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	_XNone	

5	Payment or honoraria for	_X_None	
,	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
7	Support for attending meetings and/or travel	_X_None	
	meetings and/or traver		
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	_X_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_X_None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_X_None	
12	Receipt of equipment,	X None	
12	materials, drugs, medical	X_NOTIE	
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Plea	ise summarize the above co	nflict of interest in the fol	lowing box:

None		

Please place an "X" next to the following statement to indicate your agreement:

Date: September 4, 2023 Your Name: Sukeshi Patel Arora

Manuscript Title: Pivoting to Telemedicine in a Single-Day Multidisciplinary Liver Tumor Clinic During COVID-19:

The Texas Liver Tumor Center Experience Manuscript number (if known): APM-23-357

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	X None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None CA054174	National Institutes of Health
3	Royalties or licenses	X None	
4	Consulting fees	X None	

5	Dayment or honoraria for	None	
5	Payment or honoraria for	None	Charles de Division in account for a
	lectures, presentations,	Exelixis, Bayer, Bristol	Speaker's Bureau, personal fees
	speakers bureaus,	Meyers Squibb	
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
7	Support for attending	X None	
	meetings and/or travel		
	5	V N	
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or	AstraZeneca, QED	Advisory Board, personal fees
	Safety Monitoring Board or Advisory Board	AstraZeneca, QED Therapeutics, Seagen	Advisory Board, personal fees
		•	Advisory Board, personal fees
10		•	Advisory Board, personal fees
10	Advisory Board  Leadership or fiduciary role	Therapeutics, Seagen	Advisory Board, personal fees
10	Advisory Board  Leadership or fiduciary role in other board, society,	Therapeutics, Seagen	Advisory Board, personal fees
10	Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy	Therapeutics, Seagen	Advisory Board, personal fees
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Therapeutics, Seagen  X None	Advisory Board, personal fees
	Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy	Therapeutics, Seagen	Advisory Board, personal fees
	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Therapeutics, Seagen  X None	Advisory Board, personal fees
11	Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options	Therapeutics, Seagen  X None  X None	Advisory Board, personal fees
	Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment,	Therapeutics, Seagen  X None	Advisory Board, personal fees
11	Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical	Therapeutics, Seagen  X None  X None	Advisory Board, personal fees
11	Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other	Therapeutics, Seagen  X None  X None	Advisory Board, personal fees
11 12	Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services	Therapeutics, Seagen  X None  X None  X None	Advisory Board, personal fees
11	Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-	Therapeutics, Seagen  X None  X None	Advisory Board, personal fees
11 12	Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services	Therapeutics, Seagen  X None  X None  X None	Advisory Board, personal fees
11 12	Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-	Therapeutics, Seagen  X None  X None  X None	Advisory Board, personal fees

Dr. Arora reports personal fees from Exelixis, personal fees from AstraZeneca, personal fees from QED Therapeutics,
personal fees from Bayer, personal fees from Bristol Meyers Squibb, personal fees from Seagen, outside the
submitted work; Dr. Arora is supported by National Institutes of Health (grant number CA054174).

Please place an "X" next to the following statement to indicate your agreement: